Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial
Related Posts
Henson C, Clayburgh D, Lee A, Wong D, Kudrimoti M, Lee S, Kalman N, Rao K, Sohn KY, Crawford J, Villa A, Sonis S. A[...]
Ribas A. Basic rules to respond to PD-1 blockade cancer immunotherapy. J Immunother Cancer. 2025 May 26;13(5):e012096. doi: 10.1136/jitc-2025-012096. PMID: 40425230.
Nguyen T, Shin Y, Ruppa A, Krall AS, Pham J, Chen PC, Mirmohammadi H, Keshavarz P, Finn RS, Agopian VG, French SW, Christofk HR, Lu[...]